Breast cancer in young women

Although uncommon, breast cancer in young women is worthy of special attention due to the unique and complex issues that are raised. This article reviews specific challenges associated with the care of younger breast cancer patients, which include fertility preservation, management of inherited breast cancer syndromes, maintenance of bone health, secondary prevention, and attention to psychosocial issues.

[1]  R. Fisher,et al.  Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Marks,et al.  Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Sauter,et al.  A constitutional de novo mutation in exon 8 of the p53 gene in a patient with multiple primary malignancies. , 1996, British Journal of Cancer.

[4]  T. Rebbeck,et al.  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Gelmon,et al.  Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Cella,et al.  Age‐related differences in the quality of life of breast carcinoma patients after treatment , 1999, Cancer.

[7]  R. Gelber,et al.  Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Paradiso,et al.  A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer , 2005, British Journal of Cancer.

[9]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[10]  P. Goodwin,et al.  Risk of menopause during the first year after breast cancer diagnosis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Klijn,et al.  Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. , 2004, European journal of cancer.

[12]  R. Weichselbaum,et al.  Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. , 1992, The New England journal of medicine.

[13]  D. Winchester,et al.  The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age , 1996, Cancer.

[14]  P. Dong,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[15]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[16]  T. Sellers,et al.  Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Carlo Catalano,et al.  The Challenge of Imaging Dense Breast Parenchyma: Is Magnetic Resonance Mammography the Technique of Choice? A Comparative Study With X-Ray Mammography and Whole-Breast Ultrasound , 2009, Investigative radiology.

[18]  J. Cuzick,et al.  Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. , 2003, European journal of cancer.

[19]  R. Guzman,et al.  Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Caraglia,et al.  Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients , 2007, Clinical Cancer Research.

[21]  P. Andersen,et al.  Factors influencing the effect of age on prognosis in breast cancer: population based study , 2000, BMJ : British Medical Journal.

[22]  A. Bleyer,et al.  Breast cancer before age 40 years. , 2009, Seminars in oncology.

[23]  T. Spector,et al.  A high incidence of vertebral fracture in women with breast cancer , 1999, British Journal of Cancer.

[24]  S. Singletary,et al.  Incidence and time course of bleeding after long‐term amenorrhea after breast cancer treatment , 2010, Cancer.

[25]  P. Jacobsen,et al.  Sexual Functioning in Long-Term Breast Cancer Survivors Treated with Adjuvant Chemotherapy , 2002, Breast Cancer Research and Treatment.

[26]  H. Bang,et al.  Efficiency of oocyte cryopreservation: a meta-analysis. , 2006, Fertility and sterility.

[27]  L. V. van't Veer,et al.  Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers , 2005, British Journal of Cancer.

[28]  S. Swain,et al.  Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  I. Ellis,et al.  Clinical and histological predictors of contralateral breast cancer. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[30]  H. Li,et al.  Meta-analysis of clodronate and breast cancer survival , 2007, British Journal of Cancer.

[31]  J. Donnez,et al.  Livebirth after orthotopic transplantation of cryopreserved ovarian tissue , 2004, The Lancet.

[32]  H. Bang,et al.  Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. , 2007, The oncologist.

[33]  D. Neuberg,et al.  Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Marilie D. Gammon,et al.  Breast cancers among very young premenopausal women (United States) , 2003, Cancer Causes & Control.

[35]  T. Tuttle,et al.  Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  L. Pierce,et al.  Mastectomy versus conservative surgery and radiation therapy. Psychosocial consequences , 1994, Cancer.

[37]  W. Sauerbrei,et al.  Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[39]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. Birnbaum,et al.  Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. , 2000, Cancer research.

[41]  J. Elmore,et al.  Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  L. Bjørge,et al.  How might pregnancy immunize against breast cancer? , 1998, American journal of reproductive immunology.

[43]  A. McTiernan,et al.  Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[45]  R. Sankila,et al.  Survival of breast cancer patients after subsequent term pregnancy: "healthy mother effect". , 1994, American journal of obstetrics and gynecology.

[46]  Z. Aziz,et al.  The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30 , 2009, Familial Cancer.

[47]  J. Fraumeni,et al.  Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? , 1969, Annals of internal medicine.

[48]  I. Bedrosian,et al.  Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. , 2010, Journal of the National Cancer Institute.

[49]  A. Luini,et al.  Very young women (<35 years) with operable breast cancer: features of disease at presentation. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  P. Goodwin,et al.  Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  V. Jackson.  The role of US in breast imaging. , 1990, Radiology.

[52]  R. Theriault,et al.  Breast Cancer Diagnosis during Pregnancy , 2009, Women's health.

[53]  M. Kissin,et al.  Pregnancy after breast cancer: the importance of active counselling and planning. , 2009, Breast.

[54]  R. Eeles,et al.  Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[55]  K. Oktay,et al.  Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  H. Mouridsen,et al.  Danish Breast Cancer Cooperative Group--DBCG. , 1977, Ugeskrift for laeger.

[57]  K. Oktay.  Spontaneous conceptions and live birth after heterotopic ovarian transplantation: is there a germline stem cell connection? , 2006, Human reproduction.

[58]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  E. Winer,et al.  Web-based survey of fertility issues in young women with breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[61]  J. Peterse,et al.  Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  G. Hortobagyi,et al.  Female patients with breast carcinoma age 30 years and younger have a poor prognosis , 2001, Cancer.

[63]  J. Manola,et al.  Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[65]  P. Porter,et al.  Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. , 2000, Journal of the National Cancer Institute.

[66]  S. Groshen,et al.  Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. , 1989, Surgery.

[67]  R. Greil,et al.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. , 2008, The Lancet. Oncology.

[68]  R. Gelber,et al.  Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? , 2000, The Lancet.

[69]  C. Bonaïti‐pellié,et al.  P53 germline mutations in childhood cancers and cancer risk for carrier individuals , 2000, British Journal of Cancer.

[70]  M. Ellis,et al.  Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines , 2007 .

[71]  P. Lønning,et al.  Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  D. Wallwiener,et al.  Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  M. Ewertz,et al.  Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG) , 2005, British Journal of Cancer.

[74]  Y. Englert,et al.  Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: case report. , 2006, Human reproduction.

[75]  O. Olopade,et al.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. , 2006, The Lancet. Oncology.

[76]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[77]  S. Dobie,et al.  Prophylactic mastectomy for prevention of breast cancer. , 1999, The Journal of family practice.

[78]  Clinical value of mammography for symptomatic women 35 years of age and younger. , 1999, American journal of obstetrics and gynecology.

[79]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[80]  A. Hanlon,et al.  Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  J. Cuzick,et al.  Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  R. Collins,et al.  Ovarian ablation in early breast cancer: overview of the randomised trials , 1996, The Lancet.

[83]  Sarah M. Greene,et al.  Complications following bilateral prophylactic mastectomy. , 2005, Journal of the National Cancer Institute. Monographs.

[84]  E. Perez,et al.  Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. , 2010, The New England journal of medicine.

[85]  E. Cook,et al.  Contralateral breast cancer: clinical characteristics and impact on prognosis. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  E. Schiff,et al.  Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. , 2005, The New England journal of medicine.

[87]  T. M. Kolb,et al.  Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. , 2002, Radiology.

[88]  D. Tsiftsis,et al.  Pregnancy after breast cancer. A comprehensive review , 2010, Journal of surgical oncology.

[89]  D. Evans,et al.  Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. , 1997, Cancer research.

[90]  A. Avilés,et al.  Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma , 2007, Medical oncology.

[91]  H. Kal,et al.  Breast carcinoma during pregnancy: International recommendations from an expert meeting , 2006, Cancer.

[92]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.

[93]  P. Glazer,et al.  Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status , 2002, The Lancet.

[94]  S. Cremers,et al.  Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  Rohini Sharma,et al.  LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. , 2009, The Cochrane database of systematic reviews.

[96]  C. Bonaïti‐pellié,et al.  Sensitivity and predictive value of criteria for p53germline mutation screening , 2001, Journal of medical genetics.

[97]  E. Ostrander,et al.  Frequency of BRCA1/BRCA2 mutations in a population‐based sample of young breast carcinoma cases , 2000, Cancer.

[98]  A. Porter,et al.  The diagnosis of breast cancer in women younger than 40. , 2004, Breast.

[99]  K. Horst,et al.  Locoregional management of breast cancer in women younger than 40 , 2010 .

[100]  A. Craft,et al.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. , 1994, Cancer research.

[101]  H. Adami,et al.  Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population‐based case‐control study , 1985, Cancer.

[102]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[103]  W. Eiermann,et al.  CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). , 2006, European journal of cancer.

[104]  M. Bonetti,et al.  Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. , 2003, Journal of the National Cancer Institute.

[105]  L. Vlahos,et al.  Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline , 2005, Medical Oncology.

[106]  T. Tuttle,et al.  Patient and Surgeon Characteristics Associated with Increased Use of Contralateral Prophylactic Mastectomy in Patients with Breast Cancer , 2009, Annals of Surgical Oncology.

[107]  P. Clézardin,et al.  Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. , 2007, Journal of the National Cancer Institute.

[108]  J. Andersen,et al.  Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. , 2000, American journal of surgery.

[109]  C. Bressac,et al.  Why are local recurrences after breast-conserving therapy more frequent in younger patients? , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[111]  J. Forbes,et al.  Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  Ellen Warner,et al.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  P. Patrizio,et al.  American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  J. Fraumeni,et al.  Follow-up study of twenty-four families with Li-Fraumeni syndrome. , 1991, Cancer research.

[115]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007 .